Pharmacokinetic-Pharmacodynamic Consequences and Clinical Relevance of Cytochrome P450 3A4 Inhibition
The DOI matches its Crossref record; 167 of the 167 references it cites were found in a registry or an index.
Abstract
Drug interactions occur when the efficacy or toxicity of a medication is changed by administration of another substance. Pharmacokinetic interactions often occur as a result of a change in drug metabolism. Cytochrome P450 (CYP) 3A4 oxidises a broad spectrum of drugs by a number of metabolic processes. The location of CYP3A4 in the small bowel and liver permits an effect on both presystemic and systemic drug disposition. Some interactions with CYP3A4 inhibitors may also involve inhibition of P-glycoprotein. Clinically important CYP3A4 inhibitors include itraconazole, ketoconazole, clarithromycin, erythromycin, nefazodone, ritonavir and grapefruit juice. Torsades de pointes, a life-threatening ventricular arrhythmia associated with QT prolongation, can occur when these inhibitors are coadministered with terfenadine, astemizole, cisapride or pimozide. Rhabdomyolysis has been associated with the coadministration of some 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors ('statins') and CYP3A4 inhibitors. Symptomatic hypotension may occur when CYP3A4 inhibitors are given with some dihydropyridine calcium antagonists, as well with the phosphodiesterase inhibitor sildenafil. Excessive sedation can result from concomitant administration of benzodiazepine (midazolam, triazolam, alprazolam or diazepam) or nonbenzodiazepine (zopiclone and buspirone) hypnosedatives with CYP3A4 inhibitors. Ataxia can occur with carbamazepine, and ergotism with ergotamine, following the addition of a CYP3A4 inhibitor. Beneficial drug interactions can occur. Administration of a CYP3A4 inhibitor with cyclosporin may allow reduction of the dosage and cost of the immunosuppressant. Certain HIV protease inhibitors, e.g. saquinavir, have low oral bioavailability that can be profoundly increased by the addition of ritonavir. The clinical importance of any drug interaction depends on factors that are drug-, patient- and administration-related. Generally, a doubling or more in plasma drug concentration has the potential for enhanced adverse or beneficial drug response. Less pronounced pharmacokinetic interactions may still be clinically important for drugs with a steep concentration-response relationship or narrow therapeutic index. In most cases, the extent of drug interaction varies markedly among individuals; this is likely to be dependent on interindividual differences in CYP3A4 tissue content, pre-existing medical conditions and, possibly, age. Interactions may occur under single dose conditions or only at steady state. The pharmacodynamic consequences may or may not closely follow pharmacokinetic changes. Drug interactions may be most apparent when patients are stabilised on the affected drug and the CYP3A4 inhibitor is then added to the regimen. Temporal relationships between the administration of the drug and CYP3A4 inhibitor may be important in determining the extent of the interaction.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Excessive sedation has been observed when BZDs have been used with CYP3 A4 inhibitors, such as antibiotics like clarithromycin and erythromycin.53”
From Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025) · cites this paper as [53]
Citations
Cites
Shimada, T., Yamazaki, H., Mimura, M., Inui, Y., & Guengerich, F. P. (1994) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)22379-5 · Cited by 2,785
CYTOCHROME P-450 3A4: Regulation and Role in Drug Metabolism
Guengerich, F. P. (1999) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.39.1.1 · Cited by 1,267
Nifedipine: Dose-Related Increase in Mortality in Patients With Coronary Heart Disease
Furberg, C. D., Psaty, B. M., & Meyer, J. V. (1995) · Circulation · doi:10.1161/01.cir.92.5.1326 · Cited by 1,173
IN VITRO AND IN VIVO DRUG INTERACTIONS INVOLVING HUMAN CYP3A
Thummel, K. E., & Wilkinson, G. R. (1998) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.38.1.389 · Cited by 831
Inhibition and Induction of Cytochrome P450 and the Clinical Implications
Lin, J. H., & Lu, A. Y. H. (1998) · Clinical Pharmacokinetics · doi:10.2165/00003088-199835050-00003 · Cited by 829
Grapefruit juice–drug interactions
Bailey, D. G., Malcolm, J., Arnold, O., & David Spence, J. (1998) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1998.00764.x · Cited by 740
Self-citationTorsades de Pointes Occurring in Association With Terfenadine Use
Monahan, B. P. (1990) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1990.03450210088038 · Cited by 667
Terfenadine-Ketoconazole Interaction: Pharmacokinetic and Electrocardiographic Consequences
Honig, P. K. (1993) · JAMA · doi:10.1001/jama.1993.03500120051025 · Cited by 664
Lown, K. S., Bailey, D. G., Fontana, R. J., Janardan, S. K., Adair, C. H., Fortlage, L. A., Brown, M. B., Guo, W., & Watkins, P. B. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119439 · Cited by 624
Self-citationInteraction of citrus juices with felodipine and nifedipine
Bailey, D., Spence, J., Munoz, C., & Arnold, J. M. O. (1991) · The Lancet · doi:10.1016/0140-6736(91)90872-m · Cited by 596
Self-citation
Research works printed but not linked: 32
- Lown, 1994, Drug Metab Dispos, 22, 947
- Paintaud, 1996, Therapie, 51, 384
- Shimada, 1994, J Pharmacol Exp Ther, 270, 414
- Schinkel, 1998, Int J Clin Pharmacol Ther, 36, 9
- Wandel, 1999, Cancer Res, 59, 3944
- Edwards, 1996, Drug Metab Dispos, 24, 1287
- Schmiedlin-Ren, 1997, Drug Metab Dispos, 25, 1228
- Tsai, 1997, J Formos Med Assoc, 96, 144
- Gonzalez, 1998, Int J Clin Pharmacol Ther, 36, 292
- Baciewicz, 1993, Arch Intern Med, 153, 1970, 10.1001/archinte.1993.00410170042004 · doi:10.1001/archinte.1993.00410170042004
- Assan, 1994, Diabete Metab, 20, 49
- Corpier, 1988, JAMA, 260, 239, 10.1001/jama.1988.03410020105038 · doi:10.1001/jama.1988.03410020105038 · Paper page
- Lilja, 1999, Clin Pharmacol Ther, 66, 118, 10.1053/cp.1999.v66.100453001 · doi:10.1053/cp.1999.v66.100453001 · Paper page
- Donahue, 1999, Clin Pharmacol Ther, 65, 179
- Donahue, 1999, Clin Pharmacol Ther, 65, 179
- Vincent, 1999, Clin Pharmacol Ther, 61, 233
- Uno, 1999, Clin Pharmacol Ther, 61, 209
- Sigusch, 1994, Pharmazie, 49, 522
- Fuhr, 1998, Int J Clin Pharmacol Ther, 36, 126
- Bailey, 1992, Clin Pharmacol Ther, 51, 156
- von Moltke, 1996, J Pharmacol Exp Ther, 276, 370
- Yeates, 1996, Int J Clin Pharmacol Ther, 34, 400
- Olkkola, 1996, Anesth Analg, 82, 511
- Loiseau, 1985, Presse Med, 14, 162
- Berrettini, 1986, J Clin Psychiatry, 47, 147
- Pearson, 1990, J Clin Psychiatry, 51, 126
- Preskorn, 1997, Psychopharmacol Bull, 33, 659
- Hayton, 1969, N Z Med J, 69, 42
- Ioannides-Demos, 1997, J Rheumatol, 24, 49
- Gutmann, 1999, Mol Pharmacol, 56, 383, 10.1124/mol.56.2.383 · doi:10.1124/mol.56.2.383 · Paper page
- Kupferschmidt, 1998, Br J Clin Pharmacol, 45, 355, 10.1046/j.1365-2125.1998.t01-1-00687.x · doi:10.1046/j.1365-2125.1998.t01-1-00687.x · Paper page
- Furberg, 1996, Circulation, 93, 1475
Cited by
Martignoni, M., Groothuis, G. M. M., & de Kanter, R. (2006) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2.6.875 · Cited by 1,478
“CYP3A4 and its related -3A5 are the most abundant CYP isoforms in human liver, and are involved in the biotransformation of the majority of drugs [183].”
BackgroundMetabolism and Disposition Kinetics of Nicotine
Hukkanen, J., Jacob, P., & Benowitz, N. L. (2005) · Pharmacological Reviews · doi:10.1124/pr.57.1.3 · Cited by 1,321
(2007) · PubMed · Cited by 953
Erlund, I. (2004) · Nutrition Research · doi:10.1016/j.nutres.2004.07.005 · Cited by 927
“The considerable increase in plasma concentrations of many drugs metabolized by intestinal cytochrome P-450 IIIA (CYP3A4) when administered concominantly with grapefruit juice is well documented and is of clinical relevance [67,68].”
BackgroundEnfuvirtide, an HIV-1 Fusion Inhibitor, for Drug-Resistant HIV Infection in North and South America
Lalezari, J. P., Henry, K., O'Hearn, M., Montaner, J. S. G., Piliero, P. J., Trottier, B., Walmsley, S., Cohen, C., Kuritzkes, D. R., Eron, J. J., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035026 · Cited by 914
Metadata
- Authors
- Dresser, G. K., Spence, J. D., & Bailey, D. G.
- Affiliations
- Western University (CA)
- Corresponding author
- Bailey, David G.
- Venue
- Clinical Pharmacokinetics
- Published
- 2000-01
- Volume
- 38
- Issue
- 1
- Pages
- 41-57
- ISSN
- 0312-5963 (ISSN-L)
- OpenAlex
- W2005328285
- Cited by
- 908
- References
- 165
- Citations by year
- 2026: 17 · 2025: 25 · 2024: 22 · 2023: 14 · 2022: 23 · 2021: 24 · 2020: 26 · 2019: 28 · 2018: 15 · 2017: 27 · 2016: 27 · 2015: 32 · 2014: 36 · 2013: 25 · 2012: 38
- FWCI
- 6.22
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Pharmacokinetics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Keywords
- CYP3A4 inhibitors, drug interactions, pharmacokinetic interactions, pharmacodynamic interactions, P-glycoprotein inhibition, torsades de pointes, QT prolongation, statin-induced rhabdomyolysis, benzodiazepine sedation, cyclosporine, HIV protease inhibitors, ritonavir, grapefruit juice
- MeSH terms
- Animals, Cytochrome P-450 Enzyme System, Drug Interactions, Drug Therapy, Enzyme Inhibitors, Humans, Mixed Function Oxygenases, Cytochrome P-450 CYP3A, Drug-Related Side Effects and Adverse Reactions, Cytochrome P-450 Enzyme Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacokinetic-Pharmacodynamic Consequences and Clinical Relevance of Cytochrome P450 3A4 Inhibition. https://app.cochat.ai/papers/10.2165/00003088-200038010-00003
- The paper
- Dresser, G. K., Spence, J. D., & Bailey, D. G. (2000). Pharmacokinetic-Pharmacodynamic Consequences and Clinical Relevance of Cytochrome P450 3A4 Inhibition. Clinical Pharmacokinetics. https://doi.org/10.2165/00003088-200038010-00003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.